|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-21
|
|
pubmed:abstractText |
In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-3350
|
|
pubmed:author |
pubmed-author:AfdhalNezam HNH,
pubmed-author:BoothDavid RDR,
pubmed-author:GoldsteinDavid BDB,
pubmed-author:MangiaAlessandraA,
pubmed-author:McHutchisonJohn GJG,
pubmed-author:MurrayJeffrey SJS,
pubmed-author:PawlotskyJean-MichelJM,
pubmed-author:Pharmacogenetics and Hepatitis C Meeting Participants,
pubmed-author:ShiannaKevin VKV,
pubmed-author:TanakaYasuhitoY,
pubmed-author:ThomasDavid LDL,
pubmed-author:ZeuzemStefanS
|
|
pubmed:copyrightInfo |
Copyright © 2010 American Association for the Study of Liver Diseases.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
336-45
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21254181-Antiviral Agents,
pubmed-meshheading:21254181-Clinical Trials as Topic,
pubmed-meshheading:21254181-Hepacivirus,
pubmed-meshheading:21254181-Hepatitis C, Chronic,
pubmed-meshheading:21254181-Humans,
pubmed-meshheading:21254181-Interferon-alpha,
pubmed-meshheading:21254181-Interleukins,
pubmed-meshheading:21254181-Pharmacogenetics,
pubmed-meshheading:21254181-Polyethylene Glycols,
pubmed-meshheading:21254181-Recombinant Proteins,
pubmed-meshheading:21254181-Ribavirin,
pubmed-meshheading:21254181-United States,
pubmed-meshheading:21254181-United States Food and Drug Administration,
pubmed-meshheading:21254181-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Hepatitis C pharmacogenetics: state of the art in 2010.
|
|
pubmed:affiliation |
Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. nafdhal@caregroup.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Review
|
